[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008120724A1 - 固体分散体製剤 - Google Patents

固体分散体製剤 Download PDF

Info

Publication number
WO2008120724A1
WO2008120724A1 PCT/JP2008/056105 JP2008056105W WO2008120724A1 WO 2008120724 A1 WO2008120724 A1 WO 2008120724A1 JP 2008056105 W JP2008056105 W JP 2008056105W WO 2008120724 A1 WO2008120724 A1 WO 2008120724A1
Authority
WO
WIPO (PCT)
Prior art keywords
dispersion preparation
medicinal solid
cilnidipine
medicinal
solid
Prior art date
Application number
PCT/JP2008/056105
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Higuchi
Ichiro Hara
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Priority to JP2009507521A priority Critical patent/JP5828616B2/ja
Publication of WO2008120724A1 publication Critical patent/WO2008120724A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　本発明は、水溶解性が高く、延いては消化管内での溶解性が高く、生物学的利用率の高いシルニジピン類固体分散体製剤を提供することを課題とする。該課題は、シルニジピンまたはその薬学的に許容される塩と、特定の水溶性高分子（即ち、特定のセルロース類およびその誘導体、合成高分子ならびに天然高分子および糖類）とを含む固体分散体製剤によって解決される。
PCT/JP2008/056105 2007-03-30 2008-03-28 固体分散体製剤 WO2008120724A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009507521A JP5828616B2 (ja) 2007-03-30 2008-03-28 固体分散体製剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-094659 2007-03-30
JP2007094659 2007-03-30
JP2007-209213 2007-08-10
JP2007209213 2007-08-10

Publications (1)

Publication Number Publication Date
WO2008120724A1 true WO2008120724A1 (ja) 2008-10-09

Family

ID=39808304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056105 WO2008120724A1 (ja) 2007-03-30 2008-03-28 固体分散体製剤

Country Status (3)

Country Link
JP (2) JP5828616B2 (ja)
KR (1) KR20100016093A (ja)
WO (1) WO2008120724A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5790965B2 (ja) * 2012-10-12 2015-10-07 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04360833A (ja) * 1991-06-05 1992-12-14 Fujirebio Inc １，４−ジヒドロピリジン誘導体を含有する製剤
WO1997006781A1 (fr) * 1995-08-11 1997-02-27 Nissan Chemical Industries, Ltd. Procedes permettant de rendre amorphes des medicaments peu solubles
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
WO2007029660A1 (ja) * 2005-09-06 2007-03-15 Astellas Pharma Inc. 腸溶性基剤が表面に吸着した難溶性薬物の微小粒子
JP2007308487A (ja) * 2006-04-19 2007-11-29 Ajinomoto Co Inc 固体分散体のフィルムコーティング方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
JPH05310571A (ja) * 1991-07-01 1993-11-22 Ishihara Sangyo Kaisha Ltd 非晶質性ベンゾイルウレア系化合物の抗ガン性医薬組成物
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
WO1996019239A1 (fr) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Composition solide a solubilite et absorbabilite ameliorees

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04360833A (ja) * 1991-06-05 1992-12-14 Fujirebio Inc １，４−ジヒドロピリジン誘導体を含有する製剤
WO1997006781A1 (fr) * 1995-08-11 1997-02-27 Nissan Chemical Industries, Ltd. Procedes permettant de rendre amorphes des medicaments peu solubles
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
WO2007029660A1 (ja) * 2005-09-06 2007-03-15 Astellas Pharma Inc. 腸溶性基剤が表面に吸着した難溶性薬物の微小粒子
JP2007308487A (ja) * 2006-04-19 2007-11-29 Ajinomoto Co Inc 固体分散体のフィルムコーティング方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUZUKI H. ET AL.: "Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers", CHEM. PHARM. BULL. (TOKYO), vol. 46, no. 3, 1998, pages 482 - 487, XP000748996 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5790965B2 (ja) * 2012-10-12 2015-10-07 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion

Also Published As

Publication number Publication date
JP2014058584A (ja) 2014-04-03
JP6072705B2 (ja) 2017-02-01
JPWO2008120724A1 (ja) 2010-07-15
KR20100016093A (ko) 2010-02-12
JP5828616B2 (ja) 2015-12-09

Similar Documents

Publication Publication Date Title
IL259851A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
WO2008131114A3 (en) Pharmaceutical formulations containing lipoic acid derivatives
WO2010062688A3 (en) Dosage form for insertion into the mouth
IL196979A (en) Delayed-release pharmacological system containing flibenzrin and ph-dependent polymers, process for preparation and capsule containing it
WO2008006795A3 (en) Indole compounds
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
WO2007087431A3 (en) Sublingual fentanyl spray
WO2007135193A3 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool
IL222792A0 (en) Method of coupling an oligosaccharide to a protein, oligosaccharide-protein conjugates, uses thereof and pharmaceutical compositions comprising the same
WO2007144169A3 (en) Entacapone-derivatives
WO2007016284A3 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
TW200700062A (en) Pharmaceutical compositions
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
WO2009032843A3 (en) Deuterated ethambutols and their use
EP1968606A4 (en) PREPARATION OF PHARMACEUTICAL SALTS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC ACID
WO2011011351A3 (en) A stable pharmaceutical omeprazole formulation for oral administration
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2008120724A1 (ja) 固体分散体製剤
WO2007086911A3 (en) Stable nanoparticle formulations
WO2009048940A3 (en) Diacerein pharmaceutical formulations
EP2494955A3 (en) Stable liquid pharmaceutical composition based on trazodone
AU2003235395A1 (en) Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water
WO2007016315A3 (en) Extended release venlafaxine compositions
HUP0401526A2 (en) Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739223

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009507521

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20097022769

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 08739223

Country of ref document: EP

Kind code of ref document: A1